Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
attenuated Salmonella secreting IFN-β
- Development stage
- Preclinical
- Lead developer
- Chungnam National University
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Gene Therapies, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
Attenuated Salmonella secreting IFN-β is an engineered microbial therapy developed by researchers at Chungnam National University. The platform utilizes an attenuated Salmonella Typhimurium strain (BRD509 background with an rcsB gene deletion) designed to selectively colonize and proliferate within tumor tissues. It is engineered to secrete interferon-beta (IFN-β) through the flagellar type III secretion system (FT3SS), with secretion controlled by L-arabinose induction. This localized delivery of IFN-β modulates the tumor microenvironment, promotes N1-type neutrophil infiltration, and activates antitumor immune responses. Preclinical studies in colorectal cancer models have demonstrated that the therapy inhibits tumor growth and induces apoptosis, showing significant synergistic effects when combined with PD-L1 checkpoint blockade.
- Other names
- IFN-β secreting SalmonellaFT3SS-based IFN-β secreting SalmonellarcsB-deleted BRD509 Salmonella
02
Targets
Beyond the preview
Go deeper on attenuated Salmonella secreting IFN-β.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on attenuated Salmonella secreting IFN-β.